OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 7.06
+0.05 (0.71%)
Jun 11, 2026, 4:19 PM CET
OncoZenge AB Revenue
OncoZenge AB had revenue of 71.00K SEK in the twelve months ending March 31, 2026, down -97.38% year-over-year. In the year 2025, OncoZenge AB had annual revenue of 2.78M with 278,300.00% growth.
Revenue (ttm)
71.00K
Revenue Growth
-97.38%
P/S Ratio
1,396.89
Revenue / Employee
71.00K
Employees
1
Market Cap
99.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.78M | 2.78M | 278,300.00% |
| Dec 31, 2024 | 1,000.00 | -2.00K | -66.67% |
| Dec 31, 2023 | 3.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 92.46M |
| Alzinova AB | 25.66M |
| Scandinavian ChemoTech AB | 12.61M |
| Biovica International AB | 10.93M |
| AcouSort AB | 10.05M |
| NextCell Pharma AB | 9.24M |
| Spago Nanomedical AB | 4.38M |
| Simris Group AB (PUBL) | 2.65M |
OncoZenge AB News
- 17 days ago - OncoZenge AB Quarterly report: Q1 2026 - Filings
- 3 months ago - OncoZenge AB Quarterly report: Q4 2025 - Filings
- 3 months ago - OncoZenge AB Annual report: Q4 2025 - Filings
- 8 months ago - OncoZenge AB Quarterly report: Q3 2025 - Filings
- 10 months ago - OncoZenge AB Quarterly report: Q2 2025 - Filings